- Home
- BTAI vs CDLX Comparison
BTAI vs CDLX Comparison
Compare BTAI & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | CDLX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 30.2M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BTAI | CDLX |
|---|---|---|
| Price | $1.32 | $5.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $23.00 | $2.25 |
| AVG Volume (30 Days) | ★ 720.6K | 285.8K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.63 | 50.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $233,273,000.00 |
| Revenue This Year | $197.82 | N/A |
| Revenue Next Year | $910.15 | $8.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.01 | $0.55 |
| 52 Week High | $8.08 | $6.40 |
Technical Indicators
Market Signals| Indicator | BTAI | CDLX |
|---|---|---|
| Relative Strength Index (RSI) | 61.81 | 81.86 |
| Support Level | $1.05 | $0.83 |
| Resistance Level | $1.39 | $6.40 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 83.87 | 82.22 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About CDLX Cardlytics Inc.
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.